LLY SEC Filings

Eli Lilly and Company reported robust financial performance for the fiscal year 2025, driven by significant revenue growth, primarily from its cardiometabolic products, Mounjaro and Zepbound. Total revenue reached $65.18 billion, a 45% increase year-over-year, with net income soaring by 95% to $20.64 billion. This strong performance underscores the market's demand for Lilly's innovative treatments, particularly in the areas of diabetes and obesity. The company continues to invest heavily in research and development, with a substantial pipeline including promising candidates in neuroscience and oncology. However, investors should note the increasing impact of governmental pricing regulations, such as the Inflation Reduction Act, which will influence future revenue streams for key products like Jardiance, Trulicity, and Verzenio. While the company is expanding its manufacturing capacity to meet demand, potential supply chain disruptions and evolving international trade policies remain areas to monitor.

Eli Lilly and Company (LLY) filed a 8-K Current Report on February 4, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily incorporates by reference a press release (Exhibit 99.1) containing these detailed financial outcomes. While the filing itself is brief, the associated press release is the critical document for investors seeking to understand the company's recent performance, including key revenue drivers, profitability, and any forward-looking statements or guidance provided by management.

Eli Lilly & Company (LLY) announced a significant addition to its Board of Directors, electing Dr. Carolyn R. Bertozzi, a distinguished professor from Stanford University and Howard Hughes Medical Institute investigator, effective December 8, 2025. Dr. Bertozzi brings a wealth of expertise in Chemistry, Chemical & Systems Biology, and Radiology, positions that will be highly relevant to Lilly's ongoing innovation and development in the pharmaceutical sector. Her appointment is intended to bolster the Board's strategic direction, particularly through her service on the Science and Technology Committee and the Ethics and Compliance Committee. Dr. Bertozzi's independence has been confirmed, and she will participate in the company's standard director compensation. This move signals Lilly's commitment to leveraging cutting-edge scientific knowledge at the highest governance level.

Eli Lilly and Company (LLY) reported a robust third quarter of 2025, showcasing significant growth across key financial metrics. Revenue for the quarter surged by 54% year-over-year to $17.6 billion, driven by strong volume increases from Mounjaro and Zepbound, which experienced substantial growth both in the U.S. and internationally. This top-line performance translated into impressive profitability, with net income soaring by over 470% to $5.6 billion, and diluted earnings per share reaching $6.21, up from $1.07 in the prior year period. The company's gross margin improved to 82.9%, reflecting favorable product mix and cost efficiencies. Looking at the nine-month period, the positive trends continued, with revenue up 46% to $45.9 billion and net income more than doubling to $14.0 billion. These strong results highlight the company's successful execution in bringing novel therapies to market and expanding their reach. Lilly's ongoing investment in research and development remains substantial, underscoring its commitment to future innovation, while marketing and administrative expenses also increased to support commercial launches. The balance sheet remains strong, with a significant increase in cash and cash equivalents, providing flexibility for continued investment and strategic initiatives.

Eli Lilly & Company (LLY) filed a Form 8-K on October 29, 2025, to announce its financial results for the third quarter ended September 30, 2025. The filing incorporates by reference a press release, dated October 30, 2025, which contains the detailed financial performance for the period. While the 8-K itself is brief, the attached press release (Exhibit 99.1) is expected to provide investors with crucial insights into the company's revenue, earnings per share, product sales performance, and potentially guidance for the remainder of the fiscal year.

Eli Lilly and Company (LLY) has announced the successful completion of a significant debt offering, raising approximately $6.71 billion in net proceeds after underwriting discounts and before expenses. This capital raise involves the issuance of multiple tranches of notes, including $750 million in Floating Rate Notes due 2028 and various fixed-rate notes with maturities ranging from 2028 to 2065. The fixed-rate notes carry coupon rates from 4.000% to 5.650% per annum, while the floating-rate notes are tied to Compounded SOFR plus a spread. This substantial debt issuance is likely intended to support Eli Lilly's ongoing research and development efforts, potential acquisitions, or to strengthen its balance sheet. The diversity in note maturities and the inclusion of floating-rate notes suggest a strategic approach to managing interest rate risk and financing its long-term growth initiatives. Investors should monitor how these proceeds are deployed and their impact on the company's financial leverage and future profitability.

Eli Lilly and Company (LLY) reported robust financial performance for the quarter and six months ended June 30, 2025. Revenue surged by 38% and 41% year-over-year, respectively, driven by strong demand for key products like Mounjaro and Zepbound, particularly in the U.S. market. This top-line growth translated into a significant increase in net income, up 91% for the quarter and 62% for the six-month period, with diluted EPS also showing substantial gains. The company's gross margin improved due to better production costs and product mix, even with increased R&D and SG&A expenses supporting pipeline development and commercialization efforts. Despite increased investments in research and development and marketing, Lilly demonstrated strong operational efficiency. The company also made strategic acquisitions, including Verve Therapeutics and SiteOne Therapeutics, to bolster its pipeline in cardiovascular disease and pain management, respectively. Financially, Lilly maintained a healthy cash position, though total debt increased due to recent debt issuances primarily to fund acquisitions and general business purposes. The company also continued its share repurchase program and dividend payments, reflecting a commitment to shareholder returns.

Eli Lilly & Company (LLY) has filed an 8-K report on August 7, 2025, to announce its financial results for the quarter ended June 30, 2025. The report primarily references a press release, filed as Exhibit 99.1, which contains the detailed financial outcomes for the period. Investors should refer to this press release for specifics regarding revenue, earnings, and other key financial metrics. While the 8-K itself does not provide the detailed financial figures, it serves as the official notification mechanism for the release of this information. The filing indicates that the company's financial performance for the second quarter of 2025 has been disclosed. Investors are advised to review the accompanying press release for a comprehensive understanding of Lilly's operational and financial condition as of June 30, 2025, which will inform their investment decisions.

Eli Lilly and Company (LLY) held its 2025 Annual Meeting of Shareholders on May 5, 2025, with a strong turnout of approximately 89% of outstanding shares represented. The meeting's primary focus was on voting matters, including the election of directors, advisory approval of executive compensation, and ratification of the independent auditor. All management-proposed items, such as the election of the four director nominees and the ratification of Ernst & Young LLP as the independent auditor, received overwhelming support from shareholders, indicating strong confidence in the company's leadership and governance. However, two significant shareholder proposals to amend the company's Articles of Incorporation – one to eliminate the classified board structure and another to eliminate supermajority voting provisions – failed to receive the required 80% of outstanding shares for approval. While a majority of votes cast were in favor of these changes, the high threshold for approval was not met. This outcome suggests that while a portion of shareholders desire more immediate board changes and simplified voting, the current board structure and voting requirements remain in place, supported by a significant majority.

Eli Lilly and Company (LLY) reported a strong first quarter for 2025, with revenue soaring by 45% year-over-year to $12.7 billion, driven by significant growth in key products like Mounjaro and Zepbound. Net income also saw a substantial increase of 23%, reaching $2.76 billion. This impressive performance reflects robust demand and improved gross margins, although offset by higher acquired in-process R&D charges and increased marketing expenses. The company's strategic focus on innovation and pipeline development continues, as evidenced by a significant increase in acquired in-process R&D, primarily related to the Scorpion Therapeutics acquisition. While R&D expenses saw a moderate increase, the company's commitment to developing new medicines remains a core driver of its long-term strategy. Lilly's financial position remains solid, with ample liquidity and cash flow to support its operations, ongoing investments in manufacturing capacity, and shareholder returns through its share repurchase program and dividends.

Eli Lilly & Company (LLY) has filed a Form 8-K on April 30, 2025, to report on its financial results for the quarter ended March 31, 2025. The filing primarily directs investors to an attached press release (Exhibit 99.1) for detailed information regarding the company's operational and financial performance during the first quarter of 2025. This standard procedure allows the company to disseminate its earnings information to the public promptly. Investors should review Exhibit 99.1, which contains the full financial results and management's commentary. While this 8-K filing itself does not contain the detailed financial figures, it serves as the official notification and public availability mechanism for the company's quarterly earnings announcement. Key metrics, revenue drivers, and forward-looking statements are expected to be elaborated within the press release.

Eli Lilly and Company (LLY) reported a substantial increase in revenue for the fiscal year ending December 31, 2024, with total revenue reaching $45.04 billion, a 32% increase over the prior year. This growth was primarily driven by strong performance in key products like Mounjaro and Zepbound, which saw significant revenue gains, along with continued growth from Verzenio and Taltz. The company also experienced substantial net income growth of 102%, reaching $10.59 billion, with diluted earnings per share rising to $11.71. This financial performance reflects increased volume and higher realized prices across its portfolio, particularly in the U.S. market. Lilly continues to aggressively invest in its research and development pipeline, with approximately 55 new medicine candidates in clinical development or under regulatory review. Significant progress has been made in areas such as obesity and Alzheimer's disease, with Mounjaro/Zepbound and Donanemab (Kisunla) showing promising results and regulatory approvals. The company also announced a new $15 billion share repurchase program, demonstrating confidence in its future prospects and commitment to returning capital to shareholders. However, investors should note ongoing risks related to pricing pressures, regulatory changes (such as the Inflation Reduction Act), intellectual property challenges, and potential supply chain disruptions.

Eli Lilly and Company (LLY) has filed an 8-K detailing a significant debt offering, successfully raising approximately $6.46 billion in net proceeds through the issuance of various senior notes. The offering includes $1 billion in 4.550% Notes due 2028, $1.25 billion in 4.750% Notes due 2030, $1 billion in 4.900% Notes due 2032, $1.25 billion in 5.100% Notes due 2035, $1.25 billion in 5.500% Notes due 2055, and $750 million in 5.600% Notes due 2065. This substantial capital raise will likely be utilized to support the company's ongoing research and development, clinical trials, and potential future acquisitions, aligning with its strategy to expand its product pipeline and market presence. Investors should note the diverse maturity profile and interest rates of these notes, reflecting current market conditions and Lilly's borrowing costs. The company has secured capital across short, medium, and long-term horizons, which can provide financial flexibility. The offering was registered on a Form S-3 registration statement, indicating a routine debt issuance for a company of Lilly's size and financial standing. The specifics of the underwriting agreements and note indentures are detailed in the filed exhibits for those seeking deeper financial insight.

Eli Lilly and Company (LLY) has filed a Current Report on Form 8-K dated February 6, 2025, to announce its financial results for the quarter and year ended December 31, 2024. While the 8-K itself does not contain the detailed financial figures, it explicitly incorporates by reference Exhibit 99.1, which is a press release detailing these results. Investors should refer to this press release for comprehensive information on the company's performance, including key financial metrics, revenue drivers, and potential forward-looking statements. The filing indicates that the information provided is being furnished and not deemed "filed" for certain regulatory purposes. This is standard practice for earnings releases. The primary takeaway for investors is to access the attached press release (Exhibit 99.1) to understand the company's recent financial health and outlook as presented by management.

Eli Lilly & Company (LLY) has filed an 8-K report on January 14, 2025, to announce its participation in the 2025 J.P. Morgan Healthcare Conference. During this event, the company is scheduled to provide an update on its 2024 earnings guidance and unveil its revenue guidance range for 2025. This presentation will also include discussions on broader market trends relevant to the pharmaceutical sector. Investors should note that the information being shared is part of a fireside chat and will be accompanied by a press release (Exhibit 99.1) and presentation slides, all of which will be accessible via webcast on Lilly's Investor website. While this 8-K serves to disclose the upcoming events and materials, the provided information is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same regulatory implications as formally filed financial statements. The company will make replays available for approximately 30 days.

Eli Lilly and Company (LLY) announced changes to its Board of Directors via an 8-K filing on November 19, 2024. The most significant development for investors is the appointment of Jon Moeller, the current Chairman, President, and CEO of Procter & Gamble, as a new independent director to the LLY Board, effective December 1, 2024. Mr. Moeller brings extensive experience from over two decades in finance, business, and strategy at P&G and will serve on the Audit Committee and the Directors and Corporate Governance Committee. Concurrently, the filing notes the resignation of Karen Walker from the Board, effective December 31, 2024. Ms. Walker, who has served since 2018, is expected to collaborate with the Company on digital commercial activities starting in 2025. Her resignation is confirmed not to be due to any disagreements regarding the Company's operations, policies, or practices. These board changes signal a strategic enrichment of the board's expertise with Mr. Moeller's appointment.

Eli Lilly and Company reported strong financial results for the third quarter and the first nine months of 2024, with significant revenue growth driven by key products like Mounjaro®, Zepbound®, and Verzenio®. Revenue for the quarter reached $11.4 billion, a 20% increase year-over-year, and $31.5 billion for the first nine months, up 27%. This growth was primarily fueled by strong volume increases in the U.S. for Mounjaro and Zepbound, alongside Verzenio's continued expansion. While the company experienced a net loss of $57.4 million in Q3 2023, it achieved a net income of $970.3 million in Q3 2024, and year-to-date net income more than doubled to $6.18 billion. The company's pipeline remains robust, with several new molecular entities (NMEs) and line extensions in late-stage clinical trials across key therapeutic areas. Management highlighted ongoing investments in manufacturing capacity to meet demand, particularly for tirzepatide (Mounjaro/Zepbound). Despite facing pressures from healthcare legislation like the Inflation Reduction Act (IRA) and ongoing litigation, Lilly's financial performance and strategic investments position it for continued growth.

Eli Lilly & Company (LLY) has filed an 8-K report on October 30, 2024, to announce its financial results for the quarter ended September 30, 2024. The report primarily incorporates by reference a press release (Exhibit 99.1) containing these detailed financial and operational outcomes. While the 8-K itself is procedural, the attached press release will contain the substantive information investors need regarding the company's performance. This includes key metrics such as revenue, earnings per share (EPS), and updates on the company's drug pipeline and sales, particularly for its key growth drivers. Investors should carefully review Exhibit 99.1 for the specific financial figures and strategic commentary provided by the company.

Eli Lilly and Company (LLY) has announced a significant leadership change, appointing Lucas Montarce as its new Executive Vice President and Chief Financial Officer, effective September 9, 2024. This appointment follows an extensive search and reflects Mr. Montarce's long tenure and diverse financial leadership experience within Lilly, including his most recent role as president and general manager for the Spain, Portugal, and Greece hub, and prior experience as group vice president, controller, and CFO of Lilly Research Laboratories. Investors should note that this change in CFO is typically a key event, and Mr. Montarce's compensation package includes an annualized base salary of $1,000,000 and an annualized target bonus of $1,000,000. The filing also confirms that Mr. Montarce's appointment was made without any pre-existing arrangements with other individuals, and he has no familial ties to current directors or executive officers, nor is he involved in any related-party transactions requiring disclosure under Regulation S-K. The company has attached a press release detailing this announcement as an exhibit to the 8-K filing. This transition at the CFO level is an important factor for investors to monitor as it can impact financial strategy and reporting going forward.

Eli Lilly & Company (LLY) has filed an 8-K report on August 16, 2024, primarily to announce a change in its Board of Directors. Dr. Marschall S. Runge has decided to retire from the Board, with his retirement effective August 31, 2024. The company explicitly states that this decision is not due to any disagreements concerning the Company's operations, policies, or practices. This is a standard procedural filing related to a director's departure.

Eli Lilly and Company (LLY) has announced the successful issuance and sale of $4.75 billion in aggregate principal amount of senior notes across multiple tranches, maturing between 2027 and 2064. This significant debt offering, which closed on August 14, 2024, generated net proceeds of approximately $4.96 billion after underwriting discounts. The company utilized this debt issuance to raise substantial capital, likely to support ongoing research and development, potential acquisitions, or general corporate purposes, aligning with its growth strategies in the pharmaceutical sector. Investors should note the diverse maturities and interest rates associated with these notes, ranging from 4.150% for the 2027 Notes to 5.200% for the 2064 Notes. The company has established terms for potential redemption and has outlined conditions under which the principal could become immediately due and payable in the event of a default. This financing action is a key event for the company, demonstrating its ability to access capital markets efficiently.

Eli Lilly and Company (LLY) reported strong financial results for the second quarter and first half of 2024, showcasing significant revenue and net income growth. Revenue surged by 36% year-over-year for the quarter and 31% for the first half, driven by robust sales of key products like Mounjaro®, Zepbound®, and Verzenio®. This growth was further bolstered by increased volume and higher realized prices, particularly in the U.S. market, and improved channel dynamics for their incretin medicines. Profitability also saw substantial improvement, with diluted earnings per share rising by 68% for both the quarter and the first half. This strong performance was supported by an improved gross margin, reflecting favorable pricing and product mix. While research and development and marketing, selling, and administrative expenses increased to support pipeline development and launches, the company maintained a healthy increase in net income. Eli Lilly also announced a proposed acquisition of Morphic Holding, Inc. for approximately $3.2 billion, indicating continued strategic investment in its pipeline. The company continues to invest heavily in expanding manufacturing capacity, particularly for its incretin medicines, though periodic supply tightness is still a consideration. The pipeline remains robust with numerous new medicine candidates in late-stage development across key therapeutic areas, including cardiometabolic health, immunology, neuroscience, and oncology. These developments, combined with strong financial performance, position Eli Lilly for continued growth.

Eli Lilly & Company (LLY) filed an 8-K on August 8, 2024, to report its financial results for the quarter ended June 30, 2024. The filing primarily consists of a press release, which is furnished as Exhibit 99.1, detailing the company's operational and financial performance for the period. Investors should refer to this press release for specific figures related to revenue, earnings, and other key financial metrics, as well as management's commentary on the results and outlook. This report does not contain new material information beyond the press release itself. Therefore, the most crucial insights for investors will be found within the provided financial results and any forward-looking statements or guidance shared by Eli Lilly in the accompanying press release. It's important to note that the information furnished under Item 2.02 is not considered "filed" for certain regulatory purposes, but it serves as the primary disclosure vehicle for these quarterly results.

Eli Lilly and Company (LLY) has announced a change in its Chief Financial Officer (CFO) role. Anat Ashkenazi will be stepping down from her position as executive vice president and CFO to pursue opportunities outside the pharmaceutical industry. She will remain with the company until the end of July 2024 to ensure a smooth handover of her duties. Taking over as interim CFO, effective July 15, 2024, will be Gordon Brooks. Mr. Brooks brings extensive experience to the role, having been with Eli Lilly for 29 years and holding various senior finance positions. This includes his recent role as group vice president, controller, and corporate strategy, as well as prior leadership positions in financial planning, procurement, and internal audit. The company has stated there are no specific arrangements or understandings related to his selection, no family ties to current executives, and no related-party transactions.

Eli Lilly & Co. (LLY) announced a significant leadership change via an 8-K filing on June 5, 2024. Anat Ashkenazi, the Executive Vice President and Chief Financial Officer (CFO), has resigned to pursue opportunities outside the pharmaceutical sector. Ms. Ashkenazi will continue in her role and as a member of the Executive Committee until July 2024, ensuring a smooth transition during this period. The company has initiated a comprehensive search for her successor, considering both internal and external candidates. This CFO transition comes at a critical time for Eli Lilly, a company experiencing substantial growth and development, particularly with its promising drug pipeline. While the departure of a key executive like the CFO can raise questions, Ms. Ashkenazi's commitment to serving through July provides a buffer for leadership continuity. Investors will be closely watching the selection process for her replacement and its potential impact on financial strategy and execution. The press release detailing this announcement is attached as an exhibit to the filing.

Eli Lilly and Company (LLY) held its 2024 Annual Meeting of Shareholders on May 6, 2024, where a significant majority of outstanding shares (approximately 90%) were represented. The meeting's primary outcome was the election of four director nominees to three-year terms, with overwhelming support from shareholders. Additionally, shareholders advisory approved the compensation of the Company's named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for 2024. However, two key governance proposals seeking to eliminate the classified board structure and supermajority voting provisions did not receive the required 80% of outstanding shares to pass. Several shareholder proposals regarding lobbying activities, diversity and inclusion effectiveness, the impact of patent exclusivities on product access, and the adoption of a comprehensive human rights policy also failed to gain majority approval. These voting outcomes indicate shareholder confidence in the current board and executive compensation, while also signaling a preference to maintain existing governance structures and a lack of consensus on specific governance and social responsibility initiatives presented.

Eli Lilly and Company (LLY) reported robust financial results for the first quarter of 2024, with total revenue reaching $8.77 billion, a significant 26% increase year-over-year. This growth was largely driven by strong performance in key products like Mounjaro, Zepbound, Verzenio, and Jardiance, despite supply constraints for some incretin medicines. Net income surged by 67% to $2.24 billion, translating to diluted earnings per share of $2.48, a 66% increase from the prior year's first quarter. The company continues to invest heavily in research and development, with R&D expenses increasing by 27% to $2.52 billion, reflecting its commitment to pipeline expansion. Marketing, selling, and administrative expenses also saw an increase of 12%. Despite increased operational costs, Eli Lilly demonstrated improved profitability, with gross margin as a percentage of revenue rising to 80.9%, up from 76.6% in the prior year's comparable quarter, attributed to favorable pricing and product mix. The company's financial position remains strong, with sufficient liquidity to fund operations and planned capital expenditures.

Eli Lilly and Company (LLY) filed an 8-K on April 30, 2024, primarily to furnish their first-quarter 2024 financial results via an attached press release. While this 8-K does not contain novel operational updates or strategic shifts, it directs investors to the detailed financial performance for the period ending March 31, 2024. Investors should refer to the accompanying press release (Exhibit 99.1) for comprehensive information on revenue, earnings, and other key financial metrics. The significance of this filing lies in its role as the official disclosure mechanism for Lilly's quarterly performance. The press release will contain the specific financial figures, management commentary on the results, and potentially preliminary outlook for the upcoming quarters. Investors are advised to review this press release to understand the company's current financial health and its trajectory.

Eli Lilly and Company (LLY) reported strong performance in its 2023 10-K filing, driven by significant growth in key therapeutic areas, particularly diabetes, obesity, and oncology. Revenue increased by 20% year-over-year, with notable contributions from Mounjaro, Verzenio, and Jardiance. The company is heavily investing in its late-stage pipeline, with approximately 50 new medicine candidates in clinical development or under regulatory review, including promising treatments for Alzheimer's disease (Donanemab) and obesity. This robust pipeline, coupled with strategic acquisitions like POINT Biopharma for radiopharmaceutical capabilities, positions Lilly for continued innovation and market leadership. However, the company faces ongoing challenges including intense competition, increasing government price controls (like those from the Inflation Reduction Act), and supply chain complexities for high-demand products like Mounjaro and Trulicity. Despite these headwinds, Lilly's strategic focus on innovation and expansion of manufacturing capacity provides a foundation for future growth, though investors should monitor regulatory developments and competitive pressures.

Eli Lilly and Company (LLY) announced on February 7, 2024, its successful issuance of $6.45 billion in aggregate principal amount of senior notes through an underwriting agreement with several major financial institutions. This offering comprised five tranches of notes with varying maturities ranging from 2027 to 2064 and coupon rates from 4.500% to 5.100%. The net proceeds from this significant debt issuance, totaling approximately $6.45 billion after deducting underwriting discounts, are expected to bolster Lilly's financial flexibility. This substantial capital raise indicates Lilly's strategic approach to financing its operations, research and development, and potential future growth initiatives. The diverse maturity profile of the notes allows for a structured approach to debt management. Investors should note that the company retains the option to redeem these notes under specific conditions, and the principal amount may become immediately due and payable in the event of a default, as outlined in the indenture agreement.

Eli Lilly and Company (LLY) filed an 8-K on February 6, 2024, to report its financial results for the quarter and year ended December 31, 2023. The filing incorporates by reference a press release, dated February 6, 2024, containing these results. While the 8-K itself does not detail the financial figures, it serves as the official notification mechanism for the release of this information to the public and investors. Investors should refer to the accompanying press release (Exhibit 99.1) for specific financial performance data, including revenue, earnings, and guidance for the upcoming periods.

Eli Lilly and Company (LLY) filed an 8-K on November 2, 2023, primarily to furnish a press release detailing their financial results for the third quarter ended September 30, 2023. While the 8-K itself does not contain the detailed financial data, it directs investors to the accompanying Exhibit 99.1, which is the press release. This filing signifies the official reporting of the company's quarterly performance, providing investors with key metrics on revenue, earnings, and potentially updates on their product pipeline and strategic initiatives. Investors should carefully review the press release (Exhibit 99.1) for comprehensive details on the company's financial health and operational performance during the third quarter. This includes examining the growth drivers, any significant expenses, and the outlook provided by management. The filing is crucial for understanding Lilly's current financial standing and its trajectory moving forward, especially concerning its highly anticipated drug developments.

Eli Lilly and Company (LLY) reported a significant increase in revenue for the third quarter of 2023, driven by strong sales of key products like Mounjaro® and Verzenio®, alongside revenue from the divestiture of the olanzapine portfolio. Despite the revenue growth, the company reported a net loss for the quarter, primarily due to substantial acquired in-process research and development (IPR&D) charges related to recent acquisitions, as well as increased research and development and marketing expenses. For the nine-month period ending September 30, 2023, revenue also saw a healthy increase, though net income and diluted EPS declined year-over-year. This decline is largely attributed to the same factors impacting the quarterly results: significant IPR&D expenses and higher operating costs, partially offset by robust top-line growth. The company continues to invest heavily in its late-stage pipeline, with numerous promising candidates in development across various therapeutic areas, including diabetes, obesity, immunology, neuroscience, and oncology.

Eli Lilly & Company (LLY) filed an 8-K on August 8, 2023, primarily to furnish its second-quarter 2023 financial results. The press release, attached as Exhibit 99.1, details the company's performance for the quarter ended June 30, 2023. While the filing itself is procedural, the attached press release contains the substantive financial and operational data that investors will scrutinize. Investors should focus on the details within the press release for insights into revenue growth, profitability, key product performance (especially in areas like diabetes and obesity), and any forward-looking guidance provided by the company. This 8-K serves as the official notification of the release of this crucial financial information, marking a point for market analysis of Lilly's recent performance and future outlook.

Eli Lilly and Company reported robust financial results for the second quarter and first half of 2023, demonstrating significant revenue and net income growth. Total revenue increased by 28% in the second quarter and 7% year-to-date, driven by strong volume increases in key products like Mounjaro, Verzenio, Jardiance, and Taltz, along with a notable contribution from the sale of Baqsimi rights. Net income saw a substantial rise of 85% in the quarter and 9% year-to-date, attributed to higher revenues, reduced acquired in-process R&D charges, and strategic pipeline investments. The company continues to invest heavily in research and development, with expenses increasing by 32% and 28% for the respective periods, reflecting a strong commitment to its late-stage pipeline, including promising treatments for diabetes, obesity, immunology, and neuroscience. Acquisitions, such as the announced deal for DICE Therapeutics, underscore Lilly's strategy to expand its portfolio and therapeutic reach. Despite supply chain challenges for incretin products like Mounjaro and Trulicity, the company is actively expanding manufacturing capacity to meet demand. Looking ahead, Lilly faces potential headwinds from evolving pharmaceutical pricing regulations, including the Inflation Reduction Act, but remains focused on innovation and growth.

Eli Lilly and Company (LLY) filed an 8-K report detailing the results of its 2023 Annual Meeting of Shareholders held on May 1, 2023. The report indicates strong shareholder participation, with approximately 90% of outstanding shares represented. Key outcomes include the election of four director nominees to three-year terms and the advisory approval of executive compensation. Shareholders also voted to continue advisory votes on executive compensation on an annual basis and ratified the appointment of Ernst & Young LLP as the independent auditor. Notably, proposals to eliminate the company's classified board structure and to remove supermajority voting provisions did not achieve the required 80% shareholder approval. Several shareholder proposals concerning lobbying activities, patent exclusivity impacts, abortion support risks, diversity and inclusion efforts, and political expenditure reporting were also not approved.

Eli Lilly and Company reported a decrease in revenue for the first quarter of 2023, down 11% year-over-year to $7.0 billion, primarily due to the cessation of COVID-19 antibody sales and lower realized prices. Net income also saw a significant decline of 29% to $1.34 billion, or $1.49 per diluted share. This downturn was partially offset by strong growth in key products like Mounjaro and Verzenio, and a notable improvement in gross margin percentage, driven by the shift away from lower-margin COVID-19 antibody sales. Despite the top-line decrease, the company continues to invest heavily in research and development, with expenses up 23% driven by late-stage asset development. The company also announced significant divestiture agreements for the olanzapine portfolio (Zyprexa) and Baqsimi, which are expected to close in April 2023, generating substantial cash proceeds. Eli Lilly's financial position remains robust, with an increase in cash and cash equivalents and continued share repurchases, indicating confidence in future growth prospects, particularly from its innovative pipeline.

Eli Lilly and Company (LLY) filed an 8-K on April 27, 2023, primarily to report its financial results for the quarter ended March 31, 2023. The report references an attached press release (Exhibit 99.1) containing the detailed financial outcomes for the period. While the 8-K itself does not contain the specific financial figures, it signals the public disclosure of the company's performance, which investors should review in the accompanying press release for insights into revenue, earnings, and other key financial metrics. This filing is routine for publicly traded companies and serves as a formal notification of material events. For investors, the crucial information lies within the unaudited interim financial results for the first quarter of 2023, which will provide an update on the company's operational and financial condition. Key areas to scrutinize in the press release will include product sales performance, earnings per share (EPS), any forward-looking guidance, and significant developments or challenges encountered during the quarter.

Eli Lilly & Company (LLY) filed an 8-K on March 17, 2023, to disclose a non-competition and non-solicitation agreement entered into with Daniel Skovronsky, a key officer. This agreement outlines restrictions on competitive activities and solicitation of company relationships for a period following his employment. The agreement includes a provision for Dr. Skovronsky to receive up to $5 million if the Company chooses to enforce its terms. This filing is primarily an administrative disclosure regarding executive compensation and post-employment obligations, rather than a report of significant operational changes or financial performance. Investors should note this as part of the company's standard governance practices for executive arrangements.

Eli Lilly and Company (LLY) announced on February 23, 2023, the successful issuance and sale of a substantial debt offering totaling approximately $4 billion. This offering consisted of four tranches of notes with varying maturities and coupon rates: $750 million of 5.000% Notes due 2026, $1 billion of 4.700% Notes due 2033, $1.25 billion of 4.875% Notes due 2053, and $1 billion of 4.950% Notes due 2063. The net proceeds from this offering, estimated at approximately $3.96 billion after underwriting discounts and before other expenses, are expected to provide significant financial flexibility for the company. This substantial capital raise indicates Lilly's strategic intent to strengthen its balance sheet, potentially to fund ongoing research and development, business development activities, or general corporate purposes. Investors should note the long-term nature of some of these notes, particularly the 2053 and 2063 tranches, reflecting the company's long-term financial planning and commitment to growth. The details of the underwriting agreement and the terms of the notes have been filed with the SEC, offering transparency on the transaction.

Eli Lilly and Company (LLY) reported strong performance in its 2022 10-K filing, with total revenue reaching $28.54 billion, a slight increase from the previous year, driven by volume growth in key products like Trulicity, Verzenio, Jardiance, and Taltz. The company's profitability also saw a notable increase, with net income rising 12% to $6.24 billion. This growth was underpinned by robust clinical development progress, particularly in areas like diabetes with Mounjaro and cardiovascular disease. Despite facing patent expirations for some older products like Alimta, which led to significant revenue declines in those segments, Lilly demonstrated resilience through its strong pipeline and successful launches of newer, high-growth products. The company is heavily investing in research and development, with R&D expenses increasing to $7.19 billion, reflecting its commitment to innovation in therapeutic areas such as obesity, immunology, neuroscience, and oncology. Lilly is also strategically expanding its manufacturing capabilities to meet strong demand for its incretin products. While the company faces ongoing challenges from generic competition, pricing pressures, and evolving regulatory landscapes (including the Inflation Reduction Act), its strategic focus on innovation, pipeline development, and operational efficiency positions it for continued growth and value creation for shareholders.

Eli Lilly and Company (LLY) filed an 8-K on February 2, 2023, primarily to furnish its earnings press release for the quarter and year ended December 31, 2022. While the 8-K itself is brief and mainly procedural, it directs investors to the attached Exhibit 99.1, which contains the detailed financial results and operational highlights. This press release is the key document for understanding Lilly's performance during the specified period. Investors should review the press release (Exhibit 99.1) for crucial information regarding revenue, earnings per share, product sales, and any forward-looking guidance provided by the company. This filing serves as the official channel for disseminating these important financial updates, enabling investors to assess the company's current financial health and future prospects.

Eli Lilly & Company (LLY) filed an 8-K on December 13, 2022, to announce its financial guidance for the fiscal year 2023. This filing is primarily focused on providing forward-looking financial expectations to investors, which were also discussed during a teleconference for analysts and media held on the same day. The press release containing this guidance is attached as Exhibit 99.1 to the 8-K. While the 8-K itself does not contain detailed financial results or operational updates, it serves as the official channel for disseminating the company's strategic financial outlook for the upcoming year. Investors should refer to the attached Exhibit 99.1 for the specific figures and assumptions underpinning Lilly's 2023 financial projections, which will be crucial for evaluating the company's anticipated performance and growth trajectory.

Eli Lilly & Company's 8-K filing on November 1, 2022, primarily serves to furnish their financial results for the quarter ended September 30, 2022. The press release, attached as Exhibit 99.1, contains the detailed operational and financial condition information. Investors should refer to this exhibit for specific metrics regarding the company's performance during the third quarter of 2022. While the 8-K itself is a notification of the release of financial information, it directs investors to the accompanying press release for the substantive details. This typically includes revenue figures, earnings per share, segment performance, and forward-looking guidance, all crucial for assessing the company's current financial health and future prospects.

Eli Lilly and Company (LLY) reported a solid third quarter of 2022, with revenue reaching $6.94 billion, a 2% increase year-over-year, driven by strong volume growth across key products, especially in the U.S. Diluted Earnings Per Share (EPS) also saw a significant increase of 32% to $1.61. The company's product portfolio continues to perform well, with notable growth in Trulicity, Verzenio, and Jardiance. While the company is investing heavily in research and development ($1.8 billion for the quarter) and faced some headwinds from foreign exchange rates and the phasing out of COVID-19 antibody sales, its overall financial health remains robust, supported by substantial operating cash flow and a strong balance sheet.

Eli Lilly and Company (LLY) has filed an 8-K report for the event date of October 11, 2022, to disclose estimated charges for acquired In-Process Research and Development (IPR&D) and development milestones for the third quarter of 2022. The company anticipates these charges to be approximately $62.4 million on a pre-tax basis, which is expected to result in a charge of $0.06 per share for both GAAP and non-GAAP earnings. These figures are preliminary and subject to finalization of financial closing procedures, with no assurance that actual results will not differ.

Eli Lilly and Company (LLY) reported its financial results for the second quarter and first half of 2022. For the three months ended June 30, 2022, revenue was $6.49 billion, a decrease of 4% compared to the prior year, impacted by lower realized prices and foreign exchange rates, though partially offset by increased volume. Net income for the quarter was $952.5 million, or $1.05 per diluted share, a decrease from $1.39 billion ($1.53 per diluted share) in the same period last year. For the first six months of 2022, revenue increased by 6% to $14.30 billion, while net income saw a modest increase of 4% to $2.86 billion, or $3.16 per diluted share. The company's performance was influenced by several factors, including strong volume growth in key products like Trulicity, Taltz, and Verzenio, which helped drive the year-to-date revenue increase. However, the decline in revenue for the quarter was significantly impacted by the substantial decrease in sales of COVID-19 antibodies and the ongoing generic competition for Alimta. Research and development expenses saw an increase, reflecting continued investment in late-stage assets. The company also noted substantial charges related to acquired in-process R&D and development milestones, primarily associated with a buy-out of future obligations for a PI3Kα inhibitor.

Eli Lilly and Company (LLY) filed an 8-K on August 4, 2022, primarily to announce its financial results for the quarter ended June 30, 2022. The key information regarding these results is contained within the press release attached as Exhibit 99.1. Investors should refer to this press release for details on revenue, earnings, and any other operational or financial performance metrics for the second quarter of 2022. This filing serves as the official notification of these results, indicating that the company has met its reporting obligations. While the 8-K itself is brief and procedural, the attached press release is the critical document for understanding Lilly's performance during the reported period and its implications for the company's financial condition and future outlook.

This Eli Lilly & Co. (LLY) 8-K filing announces a significant addition to its Board of Directors with the appointment of Dr. Mary Lynne Hedley, effective May 15, 2022. Dr. Hedley brings a wealth of experience in the biotechnology and oncology sectors, having co-founded TESARO, Inc., a successful oncology therapeutics company acquired by GlaxoSmithKline. Her expertise in scientific research, development, and commercialization is expected to be a valuable asset to Lilly's strategic direction. Dr. Hedley's appointment to the Board's Ethics and Compliance Committee and Science and Technology Committee underscores Lilly's commitment to robust governance and innovation. Her independence is confirmed, and she will participate in the company's standard director compensation program. This move signals Lilly's continued focus on strengthening its leadership with seasoned industry professionals.

Eli Lilly and Company (LLY) filed an 8-K on May 4, 2022, detailing material modifications to its corporate governance documents following its Annual Shareholder Meeting held on May 2, 2022. The most significant update is the amendment to the Articles of Incorporation and Bylaws, which now allows shareholders to amend the Bylaws with a majority vote, in addition to the Board of Directors. This change shifts some bylaw amendment power from the Board directly to the shareholders. While shareholders approved this change, other significant governance proposals, such as eliminating the classified board structure and removing supermajority voting provisions, did not receive the required 80% shareholder approval. Additionally, several shareholder proposals related to lobbying activities and risk oversight were not approved. The appointment of Ernst & Young LLP as the independent auditor was ratified, and the compensation of named executive officers was approved on an advisory basis. The company also reported strong voting turnout, with approximately 90% of outstanding shares participating in the meeting.